1921
Volume 98, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

A current need in the global effort to eliminate lymphatic filariasis (LF) is the availability of reliable diagnostic tools that can be used to guide programmatic decisions, especially decisions made in the final stages of the program. This study conducted in The Gambia aimed to assess antifilarial antibody levels among populations living in historically highly LF-endemic areas and to evaluate the use of serologic tools to confirm the interruption of LF transmission. A total of 2,612 dried blood spots (DBSs) collected from individuals aged 1 year and above from 15 villages were tested for antibodies to Wb123 by enzyme-linked immunosorbent assay (ELISA). A subset of DBS ( = 599) was also tested for antibodies to Bm14 by ELISA. Overall, the prevalence of Wb123 was low (1.5%, 95% confidence interval [CI] 1.1–2.1%). In 7 of 15 villages (46.7%), there were no Wb123-positive individuals identified. Individuals with positive responses to Wb123 ranged in age from 3 to 100 years. Overall, Bm14 prevalence was also low (1.5%, 95% CI 0.7–2.8%). Bm14 positivity was significantly associated with older age ( < 0.001). The low levels of antibody responses to Wb123 observed in our study strongly suggest that sustainable LF transmission has likely ceased in The Gambia. In addition, our results support the conclusion that serologic tools can have a role in guiding programmatic decision making and supporting surveillance.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0371
2018-01-10
2018-04-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/1/tpmd170371.html?itemId=/content/journals/10.4269/ajtmh.17-0371&mimeType=html&fmt=ahah

References

  1. Taylor MJ, Hoerauf A, Bockarie M, , 2010. Lymphatic filariasis and onchocerciasis. Lancet 376: 11751185.
  2. WHO, 1997. Elimination of lymphatic filariasis as a public health problem. In: Fiftieth World Health Assembly (50.29), Vol. III, 3rd edition. Geneva, Switzerland: World Health Organization.
  3. Ottesen EA, , 2006. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 61: 395441.
  4. WHO, 2016. Global programme to eliminate lymphatic filariasis: progress report, 2015. Wkly Epidemiol Rec 91: 441455.
  5. WHO, 2011. Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. Geneva, Switzerland: World Health Organization.
  6. Ottesen EA, Duke BO, Karam M, Behbehani K, , 1997. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75: 491503.
  7. Weil GJ, Ramzy RM, , 2007. Diagnostic tools for filariasis elimination programs. Trends Parasitol 23: 7882.
  8. Gass K, 2012. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate Bancroftian filariasis. PLoS Negl Trop Dis 6: e1479.
  9. Weil GJ, Lammie PJ, Weiss N, , 1997. The ICT filariasis test: a rapid-format antigen test for diagnosis of Bancroftian filariasis. Parasitol Today 13: 401404.
  10. Weil GJ, 2013. Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood. Am J Trop Med Hyg 89: 1115.
  11. Hamlin KL, Moss DM, Priest JW, Roberts J, Kubofcik J, Gass K, Streit TG, Nutman TB, Eberhard ML, Lammie PJ, , 2012. Longitudinal monitoring of the development of antifilarial antibodies and acquisition of Wuchereria bancrofti in a highly endemic area of Haiti. PLoS Negl Trop Dis 6: e1941.
  12. Muck AE, Pires ML, Lammie PJ, , 2003. Influence of infection with non-filarial helminths on the specificity of serological assays for antifilarial immunoglobulin G4. Trans R Soc Trop Med Hyg 97: 8890.
  13. Lammie PJ, Weil G, Noordin R, Kaliraj P, Steel C, Goodman D, Lakshmikanthan VB, Ottesen E, , 2004. Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis–a multicenter trial. Filaria J 3: 9.
  14. Weil GJ, Curtis KC, Fischer PU, Won KY, Lammie PJ, Joseph H, Melrose WD, Brattig NW, , 2011. A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop 120 (Suppl 1): S19S22.
  15. Kubofcik J, Fink DL, Nutman TB, , 2012. Identification of Wb123 as an early and specific marker of Wuchereria bancrofti infection. PLoS Negl Trop Dis 6: e1930.
  16. Steel C, Golden A, Kubofcik J, LaRue N, de Los Santos T, Domingo GJ, Nutman TB, , 2013. Rapid Wuchereria bancrofti-specific antigen Wb123-based IgG4 immunoassays as tools for surveillance following mass drug administration programs on lymphatic filariasis. Clin Vaccine Immunol 20: 11551161.
  17. McFadzean J, , 1954. Filariasis in Gambia and Casamance, West Africa. Trans R Soc Trop Med Hyg 48: 267273.
  18. Knight R, , 1980. Current status of filarial infections in The Gambia. Ann Trop Med Parasitol 74: 6368.
  19. Rebollo MP, Sambou SM, Thomas B, Biritwum NK, Jaye MC, Kelly-Hope L, Escalada AG, Molyneux DH, Bockarie MJ, , 2015. Elimination of lymphatic filariasis in The Gambia. PLoS Negl Trop Dis 9: e0003642.
  20. Pavluck A, Chu B, Mann Flueckiger R, Ottesen E, , 2014. Electronic data capture tools for global health programs: evolution of LINKS, an Android-, web-based system. PLoS Negl Trop Dis 8: e2654.
  21. Chandrashekar R, Curtis KC, Ramzy RM, Liftis F, Li BW, Weil GJ, , 1994. Molecular cloning of Brugia malayi antigens for diagnosis of lymphatic filariasis. Mol Biochem Parasitol 64: 261271.
  22. Ceesay SJ, 2008. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372: 15451554.
  23. Noor AM, Mutheu JJ, Tatem AJ, Hay SI, Snow RW, , 2009. Insecticide-treated net coverage in Africa: mapping progress in 2000–07. Lancet 373: 5867.
  24. Steel C, Kubofcik J, Ottesen EA, Nutman TB, , 2012. Antibody to the filarial antigen Wb123 reflects reduced transmission and decreased exposure in children born following single mass drug administration (MDA). PLoS Negl Trop Dis 6: e1940.
  25. Dewi RM, Tuti S, Ganefa S, Anwar C, Larasati R, Ariyanti E, Herjati H, Brady M, , 2015. Brugia Rapid antibody responses in communities of Indonesia in relation to the results of ‘transmission assessment surveys’ (TAS) for the lymphatic filariasis elimination program. Parasit Vectors 8: 499.
  26. Mladonicky JM, King JD, Liang JL, Chambers E, Pa’au M, Schmaedick MA, Burkot TR, Bradley M, Lammie PJ, , 2009. Assessing transmission of lymphatic filariasis using parasitologic, serologic, and entomologic tools after mass drug administration in American Samoa. Am J Trop Med Hyg 80: 769773.
  27. Shawa ST, Mwase ET, Pedersen EM, Simonsen PE, , 2013. Lymphatic filariasis in Luangwa district, south-east Zambia. Parasit Vectors 6: 299.
  28. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ, , 2006. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on Bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992999.
  29. Moss DM, Priest JW, Boyd A, Weinkopff T, Kucerova Z, Beach MJ, Lammie PJ, , 2011. Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis. Am J Trop Med Hyg 85: 229237.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0371
Loading
/content/journals/10.4269/ajtmh.17-0371
Loading

Data & Media loading...

  • Received : 09 May 2017
  • Accepted : 08 Sep 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error